Amgen Inc.

Cytokinetics, Inc.

Merck Sharp + Dohme Corp.

Alan C Cheng

Mikkel V Debenedetto

Jonathan B Houze

Zhihua Ma

Paul John Dransfield

Vatee Pattaropong

Su-Jen Lai

Xiaoqi Chen

David John Kopecky

Zice Fu

Xiaodong Wang

Richard V Connors

Julie Anne Heath

Steven H Olson

Julio Cesar Medina

Nobuko Nishimura

Gayathri Swaminath

Ning Chen

Xiaohui Du

Kevin Chao Yang

Jeffrey Thomas Mihalic

Ted Charles Judd

Jeffrey Deignan

Frank Kayser

Matthew R Kaller

Daniel B Horne

Wen-Chen Yeh

Lawrence R McGee

Michael G Johnson

Felix Gonzalez Lopez De Turiso

Bradley Paul Morgan

Chihyuan Chuang

Luke W Ashcraft

Scott E Collibee

Russell Graceffa

Alessandro Boezio

Antonio Romero

Charles Kreiman

Vinod Francis Patel

Matthew M Weiss

Qingyian Liu

Ryan D White

Richard Thomas Lewis

Albert Kudzovi Amegadzie

Vu Van Ma

Isaac E Marx

Wenyuan Qian

Thomas Dineen

Jason Brooks Human

Lars V Heumann

Michele Potashman

Ning Xi

Jian Jeffrey Chen

Joseph L Kim

Jean-Christophe P Harmange

Brian K Albrecht

Mark Henry Norman

Chung-Ming Hsieh

Patricia Lopez

Matthew Irvine Brown

Jianming Bao

Longbin Liu

Shon Booker

Qiufen May Xue

Wenge Zhong

Zhicai Wu

Liusheng Zhu

Yuan Cheng

Ana Elena Minatti

Xuelei Yan

Ming Yu

Yosup Rew

Ying-Duo Gao

Aaron C Siegmund

Sean P Brown

Xianghong Wang

Daniel La

Steven F Bellon

Chester Chenguang Yuan

Rongze Kuang

James A Brown

Hanh Nho Nguyen

Mario G Cardozo

Anthony K Ogawa

Tae-Seong Kim

Markian Myroslaw Stec

Jason A Duquette

Elizabeth M Doherty

Ana Zurisadai Gonzalez Buenrostro

Kexue Li

James Richard Falsey

Kevin Yang

Yingcai Wang

Zhihong Li

Karina Romero

Zhiqiang Zhao

Erin F DiMauro

Deborah Choquette

Jacqueline D Hicks

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Plasma kallikrein inhibitors

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

Bisamide sarcomere activating compounds and uses thereof

Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.

High affinity antibodies targeting tau phosphorylated at serine 413

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof. 

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Bisamide sarcomere activating compounds and uses therof

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein. 

Triazole pyridyl compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

Growing community of inventors

San Francisco, CA, United States of America

Alan C Cheng